Compare Medpace Holdings Inc (MEDP) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Vanguard High Dividend Yield ETF — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Vanguard High Dividend Yield ETF trades at $158.86 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 6× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Vanguard High Dividend Yield ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Vanguard High Dividend Yield ETF for 139 Days on average.
| MEDP | VYM | |
|---|---|---|
Market Cap | $16.82B | $100.80B |
Volume | 223,093 | 908,176 |
Sector | Health | — |
52-Week High | $630.19 | $167.03 |
52-Week Low | $393.42 | $137.47 |
Typical Hold Time | 14 Days | 139 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
VYM trades at $158.76, up 0.83% with a bearish technical signal. The ETF faces mixed sentiment as articles highlight its consistent dividend yield of 2.42% but note underperformance versus peers like SCHD. Support levels cluster near $156-157, while resistance sits at $159-160. Recent news questions VYM's stock selection methodology after dividend cuts in holdings like Intel and Walgreens.
Outlook remains cautious due to technical bearishness and competitive pressure from higher-yielding alternatives. Risks include concentrated exposure to dividend-cut vulnerabilities and inflation persistence. Opportunities lie in Vanguard's low-cost, diversified approach for income-focused investors, though superior total return potential exists elsewhere.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
